Figure 4.
Figure 4. Transendothelial migration to supernatants from untreated and TGF-β 1–treated MS-5 cells. NCI-H929 cells were preincubated with anti-CXCR4 antibodies, T134, or adhesion medium alone and were subjected to migration through HUVEC monolayers to lower chambers containing isolated supernatants from MS-5 cells treated with or without TGF-β 1 (+ TGF-β 1 and –TGF-β 1, respectively) (left) or to MS-5 cell cultures in the lower chambers treated for 3 days with or without TGF-β 1 (+ TGF-β 1 and –TGF-β 1, respectively) (right). To some conditions, TGF-β 1 was added to the medium (MS-5 Sup/+ TGF-β 1). Data represent the means ± SDs of duplicate samples from a representative result of 4 (left) and 2 (right) experiments. Reduction in cell migration was significant (**P < .005), according to Student 2-tailed t test.

Transendothelial migration to supernatants from untreated and TGF-β 1–treated MS-5 cells. NCI-H929 cells were preincubated with anti-CXCR4 antibodies, T134, or adhesion medium alone and were subjected to migration through HUVEC monolayers to lower chambers containing isolated supernatants from MS-5 cells treated with or without TGF-β 1 (+ TGF-β 1 and –TGF-β 1, respectively) (left) or to MS-5 cell cultures in the lower chambers treated for 3 days with or without TGF-β 1 (+ TGF-β 1 and –TGF-β 1, respectively) (right). To some conditions, TGF-β 1 was added to the medium (MS-5 Sup/+ TGF-β 1). Data represent the means ± SDs of duplicate samples from a representative result of 4 (left) and 2 (right) experiments. Reduction in cell migration was significant (**P < .005), according to Student 2-tailed t test.

Close Modal

or Create an Account

Close Modal
Close Modal